DOCSLIB.ORG

3 Regimens for Alcohol Withdrawal and Detoxification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3 Regimens for Alcohol Withdrawal and Detoxification Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE 3 Regimens for alcohol withdrawal and detoxification Chad A. Asplund, MD, Jacob W. Aaronson, DO, and Hadassah E. Aaronson, DO Department of Family Practice, DeWitt Army Community Hospital, Fort Belvoir, Va Practice recommendations withdrawal symptoms and no serious psychiatric or medical comorbidities can be safely treated in ■ Patients with mild to moderate alcohol with- the outpatient setting. Patients with history of drawal symptoms and no serious psychi- severe withdrawal symptoms, seizures or deliri- atric or medical comorbidities can be safely um tremens, comorbid serious psychiatric or med- treated in the outpatient setting (SOR: A). ical illnesses, or lack of reliable support network should be considered for detoxification in the ■ Patients with moderate withdrawal should inpatient setting. receive pharmacotherapy to treat their symptoms and reduce their risk of seizures ■ THE PROBLEM OF ALCOHOL and delirium tremens during outpatient WITHDRAWAL detoxification (SOR: A). Up to 71% of individuals presenting for alcohol ■ Benzodiazepines are the treatment of detoxification manifest significant symptoms of choice for alcohol withdrawal (SOR: A). alcohol withdrawal.4 Alcohol withdrawal is a clinical syndrome that affects people accus- ■ ln healthy individuals with mild-to-moderate tomed to regular alcohol intake who either alcohol withdrawal, carbamazepine has decrease their alcohol consumption or stop many advantages making it a first-line drinking completely. treatment for properly selected patients (SOR: A). Physiology Alcohol enhances gamma-aminobutyric acid’s n our small community hospital—with limited (GABA) inhibitory effects on signal-receiving financial and medical resources—we have neurons, thereby lowering neuronal activity, Idesigned and implemented an outpatient alco- leading to an increase in excitatory glutamate hol detoxification clinical practice guideline to pro- receptors. Over time, tolerance occurs as GABA vide cost-effective, evidence-based medical care to receptors become less responsive to neurotrans- our patients, in support of their alcohol treatment. mitters, and more alcohol is required to produce Those patients with mild-to-moderate alcohol the same inhibitory effect. When alcohol is removed acutely, the number of excitatory glu- tamate receptors remains, but without the sup- Corresponding author: Chad Asplund, MD, 5663 5 Marshall Road, Fort Belvoir, VA 22060. E-mail: pressive GABA effect. This situation leads to [email protected]. the signs and symptoms of alcohol withdrawal. JULY 2004 / VOL 53, NO 7 · The Journal of Family Practice 545 3 REGIMENS FOR ALCOHOL WITHDRAWAL AND DETOXIFICATION Symptoms medical condition. This evaluation should include Noticeable alcohol withdrawal symptoms may an assessment of coexisting medical and psychi- appear within hours of cessation or decreasing atric conditions, the severity of previous with- alcohol intake. The most common symptoms drawal symptoms, and the risk factors for with- include tremor, craving for alcohol, insomnia, drawal complications. The initial symptoms of vivid dreams, anxiety, hypervigilance, agitation, alcohol withdrawal are not specific and may irritability, loss of appetite, nausea, vomiting, mimic other serious disease conditions; therefore, headache, and sweating.5 Even without treat- the initial assessment should exclude potentially ment, most of these relatively benign symptoms serious medical and psychiatric comorbidities. resolve within hours to days. Initially, assessment of common alcohol-relat- More concerning are hallucinations, delirium ed medical problems should be conducted. These tremens (DTs), and seizures. Transient auditory complications include gastritis, gastrointestinal or visual hallucinations may occur within the first bleeding, liver disease, cardiomyopathy, pancre- 2 days of decreasing or discontinuing alcohol con- atitis, neurological impairment, electrolyte imbal- sumption, and can be separate from DTs. DTs, ances, and nutritional deficiencies. A physical which present within 2 to 4 days of the last drink examination should be performed to assess for (and can last up to 3 to 4 days), are characterized arrhythmias, congestive heart failure, hepatic or by disorientation, persistent visual and auditory pancreatic disease, infectious conditions, bleed- hallucinations, agitation and tremulousness, and ing, and nervous system impairment. autonomic signs resulting from the activation of Initial alcohol level and urine drug screen stress-related hormones. These signs include should be assessed, as recent high levels of alco- tachycardia, hypertension, and fevers. hol intake and substance abuse place the patient DTs are much more serious than the “alcohol at higher risk for complications. Unstable mood shakes”—5% of patients who experience DTs die disorders—delirium, psychosis, severe depres- from metabolic complications.6 The occurrence of sion, suicidal or homicidal ideation—while poten- DTs is 5.3 times higher in men than in women;7 tially difficult to assess during intoxication, need however, women may exhibit fewer autonomic to be considered and ruled out. symptoms, making DTs in women more difficult to diagnose.6 Stabilize the patient Grand mal seizures can occur in up to 25% of After initial assessment, vital signs (eg, heart alcoholics undergoing withdrawal.4 If alcohol- rate, blood pressure, and temperature) should be related seizures do occur, they generally do so stabilized while fluid, electrolyte, and nutritional within 1 day of cessation of alcohol intake, but disturbances are corrected. Some patients under- can occur up to 5 days later. going alcohol withdrawal may require intravenous Risk factors for prolonged or complicated fluids to correct severe dehydration resulting from alcohol withdrawal include duration of alcohol vomiting, diarrhea, sweating, and fever. consumption, the number of lifetime prior detoxi- Alcoholics are often deficient in electrolytes or fications, prior seizures, prior episodes of DTs, minerals, including thiamine, folate, and magne- and current intense craving for alcohol.6–10 sium (although replacing magnesium makes no difference in clinically meaningful outcomes) ■ BEFORE TREATMENT: (level of evidence [LOE]: 1, double-blind random- ASSESS AND STABILIZE ized controlled trial).11 All patients being treated Initial assessment of the patient for alcohol withdrawal should be given 100 mg of Before initiating treatment for alcohol withdraw- thiamine immediately and daily (LOE: 3; insuffi- al, perform a thorough assessment of the patient’s cient evidence from randomized controlled trials 546 JULY 2004 / VOL 53, NO 7 · The Journal of Family Practice THE JOURNAL OF FAMILY PRACTICE FIGURE 1 The Clinical Institute Withdrawal Assessment for Alcohol—Revised Addiction Research Foundation Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) Patient _____________________________________________ Date |—|—|—| Time ____:____ Y m d (24-hour clock, midnight=00:00) Pulse or heart rate, taken for one minute: _________ Blood pressure: ______ / ______ NAUSEA AND VOMITING—Ask “Do you feel sick to your TACTILE DISTURBANCES—Ask “Have you any itching, stomach? Have you vomited?” Observation. pins and needles sensations, any burning, any numbness, 0 no nausea and no vomiting or do you feel bugs crawling on or under your skin?” 1 mild nausea with no vomiting Observation. 2 0 none 1 very mild itching, pins and needles, burning or numbness 3 2 mild itching, pins and needles, burning or numbness 4 intermittent nausea with dry heaves 3 moderate itching, pins and needles, burning or numbness 5 4 moderately severe hallucinations 6 5 severe hallucinations 7 constant nausea, frequent dry heaves and vomiting 6 extremely severe hallucinations 7 continuous hallucinations TREMOR—Arms extended and fingers spread apart. Observation. AUDITORY DISTURBANCES—Ask “Are you more aware of 0 no tremor sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are 1 not visible, but can be felt fingertip to fingertip you hearing things you know are not there?” Observation. 2 0 not present 3 1 very mild harshness or ability to frighten 4 moderate, with patient’s arm extended 2 mild harshness or ability to frighten 5 3 moderate harshness or ability to frighten 6 4 moderately severe hallucinations 7 severe, even with arms not extended 5 severe hallucinations 6 extremely severe hallucinations PAROXYSMAL SWEATS—Observation. 7 continuous hallucinations 0 no sweat visible VISUAL DISTURBANCES—Ask “Does the light appear to be 1 barely perceptible sweating, palms moist too bright? Is its color different? Does it hurt your eyes? 2 Are you seeing anything that is disturbing to you? Are you 3 seeing things you know are not there?” Observation. 4 beads of sweat obvious on forehead 0 not present 5 1 very mild sensitivity 6 2 mild sensitivity 7 drenching sweats 3 moderate sensitivity 4 moderately severe hallucinations ANXIETY—Ask “Do you feel nervous?” Observation. 5 severe hallucinations 0 no anxiety, at ease 6 extremely severe hallucinations 1 mildly anxious 7 continuous hallucinations 2 HEADACHE, FULLNESS IN HEAD—Ask “Does your head 3 feel different? Does it feel like there is a band around your 4 moderately anxious, or guarded, so anxiety is inferred head?” Do not rate for dizziness or lightheadedness. 5 Otherwise, rate severity. 6 0 not present 7 equivalent to acute panic states as
Load more

Recommended publications
  • Nottinghamshire Primary Care Alcohol Misuse Guidelines
    Nottinghamshire Primary Care Alcohol Dependence Guidelines V5.2 Last reviewed: April Review date: August 2021 2022 Title Nottinghamshire Primary Care Alcohol Dependence Guidelines Version 5.2 Lead - Dr Stephen Willott, GP Windmill Practice, Nottingham; Clinical Lead for alcohol misuse, Nottingham Recovery Network and Public Health Department, Nottingham City Council Author / Tanya Behrendt, Senior Pharmacist (Nottingham City Locality), NHS Nottingham and Nottinghamshire CCG Nominated Apollos Clifton-Brown, Operational Manager, Nottingham Recovery Network Dr David Rhinds, Consultant Addictions Psychiatrist, Nottinghamshire Healthcare NHS Foundation Trust Lead Dr Kaanthan Jawahar, ST6 Old Age Psychiatry, Derbyshire Healthcare NHS Foundation Trust Hannah Godden, Mental Health Interface and Efficiencies Pharmacist, Nottinghamshire Healthcare NHS Foundation Trust/ NHS Nottingham and Nottinghamshire CCG Jill Theobald, Interface Efficiencies Pharmacist, NHS Nottingham and Nottinghamshire CCG Approval Date August 2019 Review Date August 2022 Section Contents Page Number i. Summary 2 1. Introduction 4 2. Scope 5 3. Aims of Community Detoxification 5 4. Identifying suitable patients 5 5. Medical risks of community detoxification 6 6. Risk reduction 6 7. Record keeping 7 8. Equipment 7 9. Preparation for home detoxification 7 10. Medication 8 11. Relapse prevention/Follow up 8 12. Reducing alcohol consumption in people with alcohol dependence 9 13. Potentially difficult situations 10 14. References and version control 10 Appendix A Diagnostic Criteria
    [Show full text]
  • The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence
    The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence United States, 1991–1992 and 2001–2002 Bridget F. Grant, Ph.D., Ph.D.,a Deborah A. Dawson, Ph.D.,a Frederick S. Stinson, Ph.D.,a S. Patricia Chou, Ph.D.,a Mary C. Dufour, M.D., M.P.H.,b Roger P. Pickering, M.S.a Background: Alcohol abuse and dependence can be disabling disorders, but accurate information is lacking on the prevalence of current Diagnostic and Statistical Manual, Fourth Edition (DSM–IV) alcohol abuse and dependence and how this has changed over the past decade. The purpose of this study was to present nationally representative data on the prevalence of 12-month DSM–IV alcohol abuse and dependence in 2001–2002 and, for the first time, to examine trends in alcohol abuse and dependence between 1991–1992 and 2001–2002. Methods: Prevalences and trends of alcohol abuse and dependence in the United States were derived from face-to-face interviews in the National Institute on Alcohol Abuse and Alcoholism’s (NIAAA) 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC: n = 43,093) and NIAAA’s 1991–1992 National Longitudinal Alcohol Epidemiologic Survey (NLAES: n = 42,862). Results: Prevalences of DSM–IV alcohol abuse and dependence in 2001–2002 were 4.65 and 3.81 percent. Abuse and dependence were more common among males and among younger respondents. The prevalence of abuse was greater among Whites than among Blacks, Asians, and Hispanics. The prevalence of dependence was higher in Whites, Native Americans, and Hispanics than Asians.
    [Show full text]
  • Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder Ismene L
    Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder Ismene L. Petrakis, James Poling, Carolyn Levinson, Charla Nich, Kathleen Carroll, Elizabeth Ralevski, and Bruce Rounsaville Background: Although disulfiram and naltrexone have been approved by the Food and Drug Administrationfor the treatment of alcoholism, the effect of these medications on alcohol use outcomes and on psychiatric symptoms is still unknown in patients with co-occurring disorderspost-traumatic stress disorder(PTSD). Methods: Patients (n = 254) with a major Axis I psychiatric disorderand comorbid alcohol dependence were treatedfor 12 weeks in a medication study at three Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram; and (2) double-blind randomization to naltrexone or placebo. This resulted in four groups: (1) naltrexone alone; (2) placebo alone; (3) disulfiram and naltrexone; or (4) disulfiram and placebo. Outcomes were measures of alcohol use, PTSD symptoms, alcohol craving, GGT levels and adverse events. Results: 93 individuals (36.6%) met DSM-IV criteriafor PTSD. Subjects with PTSD had better alcohol outcomes with active medication (naltrexone, disulfiram or the combination) than they did on placebo; overallpsychiatric symptoms of PTSD improved. Individuals with PTSD were more likely to report some side effects when treated with the combination. Conclusions: The results of this study suggest that disulfiram and naltrexone are effective and safe for individuals with PTSD and comorbid alcohol dependence. Key Words: Alcohol, disulfiram, dual diagnosis, naltrexone, Post PTSD symptoms in non-alcohol dependent individuals because of its mechanism of action on the opioid receptor. Two early Traumatic Stress Disorder (PTSD) reports showed improvements in PTSD symptoms with naltrex one (Bills and Kreisler 1993) and the opioid antagonist nalmefene Naltrexone and disulfiram are two of only three medica (Glover 1993) in patients diagnosed with PTSD.
    [Show full text]
  • Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum
    International Journal of Environmental Research and Public Health Review Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum Hiroshi Mitoma 1,* , Mario Manto 2,3 and Aasef G. Shaikh 4 1 Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan 2 Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000 Charleroi, Belgium; [email protected] 3 Service des Neurosciences, University of Mons, 7000 Mons, Belgium 4 Louis Stokes Cleveland VA Medical Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44022, USA; [email protected] * Correspondence: [email protected] Abstract: Ethanol consumption remains a major concern at a world scale in terms of transient or irreversible neurological consequences, with motor, cognitive, or social consequences. Cerebellum is particularly vulnerable to ethanol, both during development and at the adult stage. In adults, chronic alcoholism elicits, in particular, cerebellar vermis atrophy, the anterior lobe of the cerebellum being highly vulnerable. Alcohol-dependent patients develop gait ataxia and lower limb postural tremor. Prenatal exposure to ethanol causes fetal alcohol spectrum disorder (FASD), characterized by permanent congenital disabilities in both motor and cognitive domains, including deficits in general intelligence, attention, executive function, language, memory, visual perception, and commu- nication/social skills. Children with FASD show volume deficits in the anterior lobules related to sensorimotor functions (Lobules I, II, IV, V, and VI), and lobules related to cognitive functions (Crus II and Lobule VIIB). Various mechanisms underlie ethanol-induced cell death, with oxidative stress and Citation: Mitoma, H.; Manto, M.; Shaikh, A.G. Mechanisms of endoplasmic reticulum (ER) stress being the main pro-apoptotic mechanisms in alcohol abuse and Ethanol-Induced Cerebellar Ataxia: FASD.
    [Show full text]
  • Alcohol-Medication Interactions: the Acetaldehyde Syndrome
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Borja-Oliveira, J Pharmacovigilance 2014, 2:5 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000145 Review Article Open Access Alcohol-Medication Interactions: The Acetaldehyde Syndrome Caroline R Borja-Oliveira* University of São Paulo, School of Arts, Sciences and Humanities, São Paulo 03828-000, Brazil *Corresponding author: Caroline R Borja-Oliveira, University of São Paulo, School of Arts, Sciences and Humanities, Av. Arlindo Bettio, 1000, Ermelino Matarazzo, São Paulo 03828-000, Brazil, Tel: +55-11-30911027; E-mail: [email protected] Received date: August 21, 2014, Accepted date: September 11, 2014, Published date: September 20, 2014 Copyright: © 2014 Borja-Oliveira CR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Medications that inhibit aldehyde dehydrogenase when coadministered with alcohol produce accumulation of acetaldehyde. Acetaldehyde toxic effects are characterized by facial flushing, nausea, vomiting, tachycardia and hypotension, symptoms known as acetaldehyde syndrome, disulfiram-like reactions or antabuse effects. Severe and even fatal outcomes are reported. Besides the aversive drugs used in alcohol dependence disulfiram and cyanamide (carbimide), several other pharmaceutical agents are known to produce alcohol intolerance, such as certain anti-infectives, as cephalosporins, nitroimidazoles and furazolidone, dermatological preparations, as tacrolimus and pimecrolimus, as well as chlorpropamide and nilutamide. The reactions are also observed in some individuals after the simultaneous use of products containing alcohol and disulfiram-like reactions inducers.
    [Show full text]
  • AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM and ACAMPROSATE in the TREATMENT of ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA
    Alcohol & Alcoholism Vol. 40, No. 6, pp. 545–548, 2005 doi:10.1093/alcalc/agh187 Advance Access publication 25 July 2005 AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM AND ACAMPROSATE IN THE TREATMENT OF ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA Get Well Clinic And Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India (Received 11 March 2005; first review notified 6 June 2005; in final revised form 21 June 2005; accepted 2 July 2005; advance access publication 25 July 2005) Abstract — Aims: To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice. Methods: One hundred alcoholic men with family members who would encourage medication compliance and accom- pany them for follow-up were randomly allocated to 8 months of treatment with DSF or ACP. Weekly group psychotherapy was also available. The psychiatrist, patient, and family member were aware of the treatment prescribed. Alcohol consumption, craving, and adverse events were recorded weekly for 3 months and then fortnightly. Serum gamma glutamyl transferase was measured at the start Downloaded from https://academic.oup.com/alcalc/article/40/6/545/125907 by guest on 27 September 2021 and the end of the study. Results: At the end of the trial, 93 patients were still in contact. Relapse (the consumption of >5 drinks/40 g of alcohol) occurred at a mean of 123 days with DSF compared to 71 days with ACP (P = 0.0001). Eighty-eight per cent of patients on DSF remained abstinent compared to 46% with ACP (P = 0.0002).
    [Show full text]
  • Alcohol Use Disorder
    Section: A B C D E Resources References Alcohol Use Disorder (AUD) Tool This tool is designed to support primary care providers (family physicians and primary care nurse practitioners) in screening, diagnosing and implementing pharmacotherapy treatments for adult patients (>18 years) with Alcohol Use Disorder (AUD). Primary care providers should routinely offer medication for moderate and severe AUD. Pharmacotherapy alone to treat AUD is better than no therapy at all.1 Pharmacotherapy is most effective when combined with non-pharmacotherapy, including behavioural therapy, community reinforcement, motivational enhancement, counselling and/or support groups. 2,3 TABLE OF CONTENTS pg. 1 Section A: Screening for AUD pg. 7 Section D: Non-Pharmacotherapy Options pg. 4 Section B: Diagnosing AUD pg. 8 Section E: Alcohol Withdrawal pg. 5 Section C: Pharmacotherapy Options pg. 9 Resources SECTION A: Screening for AUD All patients should be screened routinely (e.g. annually or when indicators are observed) with a recommended tool like the AUDIT. 2,3 It is important to screen all patients and not just patients eliciting an index of suspicion for AUD, since most persons with AUD are not recognized. 4 Consider screening for AUD when any of the following indicators are observed: • After a recent motor vehicle accident • High blood pressure • Liver disease • Frequent work avoidance (off work slips) • Cardiac arrhythmia • Chronic pain • Rosacea • Insomnia • Social problems • Rhinophyma • Exacerbation of sleep apnea • Legal problems Special Patient Populations A few studies have reviewed AUD in specific patient populations, including youth, older adults and pregnant or breastfeeding patients. The AUDIT screening tool considered these populations in determining the sensitivity of the tool.
    [Show full text]
  • Prevention of Alcohol Abuse and Illicit Drug Use Annual Awareness and Prevention Program Notice to System Offices Employees
    Prevention of Alcohol Abuse and Illicit Drug Use Annual Awareness and Prevention Program Notice to System Offices Employees Alcohol abuse and illicit drug use disrupt the work and learning environment and create an unsafe and unhealthy workplace. To protect its employees and students and fully serve the citizens of Texas, The Texas A&M University System prohibits alcohol abuse and illicit drug use. This brochure, which is distributed annually, serves as an awareness and prevention tool for System Offices employees by providing basic information about A&M System policy and regulations, legal sanctions and health risks related to alcohol abuse and illicit drug use. Information about counseling, treatment and rehabilitation programs is included. As an employee of The Texas A&M University System, motivation. Drug use by a pregnant woman may cause you must abide by state and federal laws on controlled additional health complications in her unborn child. substances, illicit drugs and use of alcohol. In addition, you must comply with A&M System policy, which states: A&M System Sanctions The Texas A&M University System (system) strictly The A&M System’s drug and alcohol abuse policy and prohibits the unlawful manufacture, distribution, regulation are included in the System Orientation course possession or use of illicit drugs or alcohol on reviewed by new employees as part of their orientation. system property, and/or while on official duty and/or The policy and regulation are posted online at as part of any system activities. http://policies.tamus.edu/34-02.pdf and http://policies.tamus.edu/34-02-01.pdf.
    [Show full text]
  • Alcohol Dependence, Withdrawal, and Relapse
    Alcohol Dependence, Withdrawal, and Relapse Howard C. Becker, Ph.D. Continued excessive alcohol consumption can lead to the development of dependence that is associated with a withdrawal syndrome when alcohol consumption is ceased or substantially reduced. This syndrome comprises physical signs as well as psychological symptoms that contribute to distress and psychological discomfort. For some people the fear of withdrawal symptoms may help perpetuate alcohol abuse; moreover, the presence of withdrawal symptoms may contribute to relapse after periods of abstinence. Withdrawal and relapse have been studied in both humans and animal models of alcoholism. Clinical studies demonstrated that alcohol­dependent people are more sensitive to relapse­ provoking cues and stimuli than nondependent people, and similar observations have been made in animal models of alcohol dependence, withdrawal, and relapse. One factor contributing to relapse is withdrawal­related anxiety, which likely reflects adaptive changes in the brain in response to continued alcohol exposure. These changes affect, for example, the body’s stress response system. The relationship between withdrawal, stress, and relapse also has implications for the treatment of alcoholic patients. Interestingly, animals with a history of alcohol dependence are more sensitive to certain medications that impact relapse­like behavior than animals without such a history, suggesting that it may be possible to develop medications that specifically target excessive, uncontrollable alcohol consumption. KEY WORDS: Alcoholism; alcohol dependence; alcohol and other drug (AOD) effects and consequences; neuroadaptation; AOD withdrawal syndrome; AOD dependence relapse; pharmacotherapy; human studies; animal studies he development of alcohol expectations about the consequences of drinking (Koob and Le Moal 2008). dependence is a complex and alcohol use.
    [Show full text]
  • Alcohol Abuse and Acute Lung Injury and Acute Respiratory Distress
    Journal of Anesthesia & Critical Care: Open Access Review Article Open Access Alcohol abuse and acute lung injury and acute respiratory distress syndrome Introduction Volume 10 Issue 6 - 2018 Alcohol is one of the most commonly used and abused beverage Fadhil Kadhum Zwer Aliqa worldwide. Alcohol is known to have numerous systemic health Private clinic practice, Iraq effects, including on the liver and central nervous system. From a respiratory standpoint, alcohol abuse has long been associated with Correspondence: Fadhil Kadhum Zwer Aliqaby, Private clinic practice, Iraq, Email an increased risk of pneumonia. More recently, alcohol abuse has been strongly linked in epidemiologic studies to development of Received: December 11, 2017 | Published: November 28, ARDS in at-risk patients. The first demonstration of an association 2018 between chronic alcohol abuse and ARDS was made by Moss et al, who retrospectively examined 351 patients at risk for ARDS.1 In this subsequent decreased phagocytosis and bacterial killing. Chronic cohort, 43% of patients who chronically abused alcohol developed alcohol use is similarly associated with altered neutrophil function and ARDS compared to only 22% of those who did not abuse alcohol, decreased superoxide production. Interestingly, chronic alcohol use with the effect most pronounced in patients with sepsis. This study decreases levels of granulocyte/macrophage colony stimulating factor was limited by its retrospective design, particularly since this design (GM-CSF) receptor and signaling in lung epithelium, which has been required that alcohol use history be obtained by chart review and shown to result in defective alveolar macrophage maturation. The documented history; furthermore, this study did not adjust for net effect of these abnormalities is an increased pulmonary bacterial concomitant cigarette smoking.
    [Show full text]
  • Pennsylvania Drug and Alcohol Abuse Control Act."
    § 1690.101. Short title This act shall be known and may be cited as the "Pennsylvania Drug and Alcohol Abuse Control Act." § 1690.102. Definitions (a) The definitions contained and used in the Controlled Substance, Drug, Device and Cosmetic Act shall also apply for the purposes of this act. (b) As used in this act: "CONTROLLED SUBSTANCE" means a drug, substance, or immediate precursor in Schedules I through V of the Controlled Substance, Drug, Device and Cosmetic Act. "COUNCIL" means the Pennsylvania Advisory Council on Drug and Alcohol Abuse established by this act. "COURT" means all courts of the Commonwealth of Pennsylvania, including magistrates and justices of the peace. "DEPARTMENT." The Department of Health. "DRUG" means (i) substances recognized in the official United States Pharmacopeia, or official National Formulary, or any supplement to either of them; and (ii) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; and (iii) substances (other than food) intended to affect the structure or any function of the body of man or other animals; and (iv) substances intended for use as a component of any article specified in clause (i), (ii) or (iii), but not including devices or their components, parts or accessories. "DRUG ABUSER" means any person who uses any controlled substance under circumstances that constitute a violation of the law. "DRUG DEPENDENT PERSON" means a person who is using a drug, controlled substance or alcohol, and who is in a state of psychic or physical dependence, or both, arising from administration of that drug, controlled substance or alcohol on a continuing basis.
    [Show full text]
  • 6.14 Alcohol Use Disorders and Alcoholic Liver Disease
    6. Priority diseases and reasons for inclusion 6.14 Alcohol use disorders and alcoholic liver disease See Background Paper 6.14 (BP6_14Alcohol.pdf) Background The WHO estimates that alcohol is now the third highest risk factor for premature mortality, disability and loss of health worldwide.1 Between 2004 to 2006, alcohol use accounted for about 3.8% of all deaths (2.5 million) and about 4.5% (69.4 million) of Disability Adjusted Life Years (DALYS).2 Europe is the largest consumer of alcohol in the world and alcohol consumption in this region emerges as the third leading risk factor for disease and mortality.3 In European countries in 2004, an estimated one in seven male deaths (95 000) and one in 13 female deaths (over 25 000) in the 15 to 64 age group were due to alcohol-related causes.3 Alcohol is a causal factor in 60 types of diseases and injuries and a contributing factor in 200 others, and accounts for 20% to 50% of the prevalence of cirrhosis of the liver. Alcohol Use Disorders (AUD) account for a major part of neuropsychiatric disorders and contribute substantially to the global burden of disease. Alcohol dependence accounts for 71% of all alcohol-related deaths and for about 60% of social costs attributable to alcohol.4 The acute effects of alcohol consumption on the risk of both unintentional and intentional injuries also have a sizeable impact on the global burden of disease.2 Alcoholic liver disease (ALD) is the commonest cause of cirrhosis in the western world, and is currently one of the ten most common causes of death.5 Liver fibrosis caused by alcohol abuse and its end stage, cirrhosis, present enormous problems for health care worldwide.
    [Show full text]